• 24 August, 2025

Sun Pharma gets USFDA nod for generic Ganirelix Acetate Injection

December 03, 2018 | Monday | News

The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL

Sun Pharmaceutical Industries Ltd., a generic pharmaceutical company today announced that it has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for a generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.

The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL.

As per IQVIA, Ganirelix Acetate Injection, 250 mcg/0.5 mL had annual sales of approximately US$ 67 million in the US for the 12 months ended September 2018. The commercialization of this product in the US market is expected in Q4FY19.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Can Policy Reforms & Investments Trigger India’s MedTech Makeover?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy